Administration of rIL-33 Restores Altered mDC/pDC Ratio, MDSC Frequency, and Th-17/Treg Ratio during Experimental Cerebral Malaria

• Published in: Pathogens (Basel) Vol. 13; no. 10; p. 877
• Main Authors: Mukherjee, Saikat, Ghosh, Pronabesh, Ghosh, Soubhik, Sengupta, Anirban, Sarkar, Samrat, Chatterjee, Rimbik, Saha, Atreyee, Bawali, Sriparna, Choudhury, Abhishek, Daptary, Altamas Hossain, Gangopadhyay, Anwesha, Keswani, Tarun, Bhattacharyya, Arindam
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.10.2024; MDPI
• Subjects: Cytokines; Dendritic cells; Dendritic structure; Disease; Ethylenediaminetetraacetic acid; Glucose metabolism; Glycolysis; Health aspects; Helper cells; Homeostasis; immune balance; Immune system; Immunoregulation; Infections; Inflammation; Interleukin 12; Laboratory animals; Lymphocytes T; Malaria; mDC/pDC; MDSCs; Mortality; Neutrophils; Parasites; Phenotypes; Polarization; rIL-33; Suppressor cells; Survivability; T cells; Th17/Treg; Vector-borne diseases; India; United States > US; Mumbai India; immune balance; rIL-33; MDSCs; mDC/pDC; malaria; Th17/Treg
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens13100877

The onset of malaria causes the induction of various inflammatory markers in the host's body, which in turn affect the body's homeostasis and create several cerebral complications. Polarization of myeloid-derived suppressor cells (MDSCs) from the classically activated M1 to alternatively activated M2 phenotype increases the secretion of pro-inflammatory molecules. Treatment with recombinant IL-33 (rIL-33) not only alters this MDSC's polarization but also targets the glycolysis pathway of the metabolism in MDSCs, rendering them less immunosuppressive. Along with that, the Helper T-cells subset 17 (Th17)/T regulatory cells (Tregs) ratio is skewed towards Th17, which increases inflammation by producing more IL-17. However, treating with rIL-33 also helps to restore this ratio, which brings back homeostasis. During malaria infection, there is an upregulation of IL-12 production from dendritic cells along with a distorted myeloid dendritic cells (mDC)/plasmacytoid dendritic cells (pDC) ratio towards mDCs promoting inflammation. Administering rIL-33 will also subvert this IL-12 production and increase the population of pDC in the host's immune system during malaria infection, thus restoring mDC/pDC to homeostasis. Therefore, treatment with rIL-33 to reduce the pro-inflammatory signatures and maintenance of immune homeostasis along with the increase in survivability could be a potential therapeutic approach for cerebral malaria.